Analyst: All of the building blocks for Genmab's upgrade were in place

Novartis, Horizon and Janssen have all reported good results for the drugs from which Genmab receives royalties. It therefore doesn't come as a surprise that the company has chosen to upgrade its financial huidance shortly before the release of its report, says an analyst at Sydbank.

Photo: Lars Møller / Genmab / PR

Over the past 14 days, news of drug sales surpassing expectations has trickled in from Genmab's partners, who pay royalties from the sales of Genmab-developed drugs. It should therefore come as no surprise that the company upgraded its financial expectations on Thursday night, says Senior Analyst at Sydbank Søren Løntoft Hansen.

"The past forenight, Johnson & Johnson has returned with a better sales of Darzalex than what was anticipated, Novartis's Kesimpta sales, too, exceeded expectations, and Horizon Therapeutics also beat expectations with Tepezza. So, all the building blocks for a Genmab upgrade were there," he says, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs